Resilient Medical Corp Joins Competitive Jumpstart Health-Tech Accelerator with Bravo™ Device

Resilient Medical Corp made its Place in the Competitive Jumpstart Trailblazer Health-tech Accelerator

Announcement

The Resilient Medical Corp, the leading manufacturer and developer of an excellent implantable medical device that diminishes risk and seamlessly heals breast cancer patients, retained its position in the rising competitive jumpstart trailblazer healthtech accelerator. The program in Cleveland is an ambitious platform for Ohio's healthcare startups, providing needed support and complex resources to bolster innovation and build startups for venture capital investment.

The resilient is marketing its BravoTM device, which will help repair soft tissue surgical wounds with long-term use, focusing on identifying the trauma-based and invasiveness with lumpectomies. This defines a reduced stress and smooth recovery from breast cancer with overall enhancement, not in mental and cosmetic health.

BravoTM

The BravoTM device provides three prominent benefits. The first benefit is due to the 3D mesh structure that discards the requirement for the follow-up cosmetic reconstruction, as it automatically combines with the patient’s tissues. Secondly, it dissolves in 12-18 months, so it eliminates the need for additional procedures. Lastly, the BravoTM device delivers as a radiocontrast maker mainly for post-operative adjuvant therapies. It is commonly found in most breast cancer lumpectomy cases.

Been a part of the accelerator, resilient smartly pitched the bravo to a vast healthcare stakeholders such as patients, health systems, commercial partners, payers, and physicians. After gaining capital, the company is further stepping forward in clinical trials.

Resilient is a client of the Ohio University Innovation Center (IC). It's a tech startup incubator that contributes to the healthtech accelerator application. The company’s key investors are venture organization TechGrowth Ohio (TGO). The TGO enables talent development, investment, and services to the qualified companies.

Views and Statements from the Company Leaders

Vice president of tech services and network management at Jumpstart, an entrepreneur support organization, Kaleigh Gallagher said, “The healthcare accelerator is introduced to support participants to level up. They receive a deep insight into the clinical, reimbursement, commercialization, and regulatory strategies. This consists of quantifying clinical and economic potency, along with forming a way for commercialization as a preparedness to hype capital, elaborate commercial value, and map the regulatory path.”

CEO and Founder of Resilient Medical Corp, Andrew Weems, explained, “While lumpectomies reflect fewer complications than mastectomies, consisting of reduced cost, short surgical time, and patient risk, they compromise with patients’ cosmetic restoration nd healing. This recent standard of treatment for lumpectomy patients includes closing of the surgical site and letting the resulting void heal naturally without any other support.”